Aminologics Co., Ltd.
USPTO PatentsView assignee record - 8 granted patents across 6 technology areas, recorded in grant years 2017–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07C (Acyclic OR Carbocyclic Compounds).
The verdict
According to USPTO PatentsView, Aminologics ranks #30,818 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 6 technology areas.
- #30,818
- of 49,997 US assignees by volume
- 6th percentile
- by Innovation Score (19.8/100)
- 5.9
- avg claims per patent
- -86%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R30818 · Foreign Corporation #30,818 · 8 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-LOW · CLAIMS-SPARSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 8 grants
- MID-PACK #30,818/49,997
- PHOTO-FINISH Amend2
- CPC-NARROW C07C · 6 areas
- INNOV-LOW 19.8/100
- CLAIMS-SPARSE 5.9 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -86% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Amend2, LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Aminologics’s 19.8 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Aminologics
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Aminologics · this assignee 20
Aminologics · this assignee
20 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Aminologics's Innovation Score is 19.8/100 (6th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Aminologics?
Each dot is one of Aminologics’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Aminologics’s own 5.9 claims/patent is at or below the 14.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Aminologics's grants concentrate
Aminologics Co., Ltd. is a focused PatentsView assignee: 6 CPC subclasses with 87.5% of grants classified under C07C (Acyclic OR Carbocyclic Compounds). Peak complete grant year is 2017 (3 grants) versus a trough of 1 in 2020. By volume, Aminologics sits between Amend2, LLC and Ampsource Biopharma Shanghai Inc..
Who files at Aminologics's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Amend2
Amend2, LLC
8 patents
- American Traffic…
American Traffic Solutions, Inc.
8 patents
- AMI Investments
AMI Investments, LLC
8 patents
- Amino UP Chemical
Amino UP Chemical Co., Ltd.
8 patents
- Amira Pharmaceuti…
Amira Pharmaceuticals, Inc.
8 patents
- Amita
Amita Technologies Inc.
8 patents
- Ampac
Ampac Limited
8 patents
- Ampsource Biophar…
Ampsource Biopharma Shanghai Inc.
8 patents
- Aminologics ◀
Aminologics Co., Ltd.
8 patents
What this shows Aminologics holds 8 patents at rank #30,767, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Aminologics
By rank, the assignees closest to #30,767 in granted patent volume.
- Amend2, LLC #30,763 · 8 patents
- American Traffic Solutions, Inc. #30,764 · 8 patents
- AMI Investments, LLC #30,765 · 8 patents
- Amino UP Chemical Co., Ltd. #30,766 · 8 patents
- Amira Pharmaceuticals, Inc. #30,768 · 8 patents
- Amita Technologies Inc. #30,769 · 8 patents
- Ampac Limited #30,770 · 8 patents
- Ampsource Biopharma Shanghai Inc. #30,771 · 8 patents
Leaders in C07C (Acyclic OR Carbocyclic Compounds)
Other assignees with the most granted patents in Aminologics's primary technology class.
Aminologics's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
20 6th percentile higher than 6% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 3 | 37.5% |
| 2018 | 2 | 25.0% |
| 2019 | 2 | 25.0% |
| 2020 | 1 | 12.5% |
Which technologies does Aminologics Co., Ltd. patent most?
Top 6 of 6 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Aminologics Co., Ltd.'s patent record in context - here's where to go next.
- Aminologics Co., Ltd.'s lead technology class is C07C (Acyclic OR Carbocyclic Compounds), 87.5% of its portfolio - see every assignee active in that class. Explore C07C
- Ranked #30,818 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Aminologics Co., Ltd. against Amend2, LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 19.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.